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Abstract
Notch signaling plays an important role in several cellular functions including growth, differ-
entiation, cell fate determination and stemness. Increased Notch activity has been linked to
several types of cancers. Activation of Notch signaling is triggered by the interaction of
Notch receptors (Notch1-4) with 5 different ligands (Jagged1-2 and Dll1-3-4) expressed on
the neighbouring cells. Currently, indirect approaches to inhibit Notch signalling are based
on the inhibition of the key step of Notch activation catalyzed by the γ-Secretase and thereby
affect several different γ-Secretase substrates; conversely direct strategies get advantage
of antibody-based drugs. The evidence that Jagged-mediated Notch activation plays a key
role in cancer cell biology and the interplay with the surrounding microenvironment
prompted us to develop a strategy to directly inhibit Notch activation by uncoupling its inter-
action with the Jagged, using an unprecedented approach based on small molecules. We
set-up a screening strategy based on: protein::protein docking of crystallographic structures
of Notch1 with Jagged1; comparative modelling of the Notch2:Jagged2 complex, based on
the Notch1::Jagged1 complex; in silico high-throughput screening directed to Notch2 inter-
action surface of a virtual chemical library containing a large variety of molecules commer-
cially available. The predicted pharmacological activity of the selected compounds was
validated in vitro by a gene reporter and a viability assay. This approach led to the success-
ful identification of two candidates with different anti-proliferative potency and efficacy. This
represents the first step towards the rational identification of candidate molecules for the
development of entirely novel drugs directed to inhibit Notch signaling in cancer.
Introduction
Notch signaling is activated through cell-cell communication in several physiologic and patho-
logic processes as the result of the engagement of Notch receptors at cell surface by their
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ligands located on the neighboring cells. Mammals express four different receptor isoforms,
named Notch1, 2, 3 and 4, and two families of ligands, Jagged1 and 2, and Delta-like (Dll) 1, 3
and 4. Upon ligand binding, two proteolytic cleavages release the intracellular Notch portion
(ICN) which translocates to the nucleus and triggers the CSL (CBF1/Su(H)/Lag-1) transcrip-
tion factor to transactivate the Notch target genes. Many of these genes are positive regulators
of proliferation and survival and include c-Myc, Bcl2, HES1 [1], or are involved in the down-
stream regulation of anti-apoptotic/proliferative pathways such as AKT, NF-κB, Wnt and oth-
ers [2]. Notch signaling has also been reported to play a crucial role in the regulation of stem
cell and cancer stem cell renewal [3].
Alterations in Notch signaling cause wide modifications in cell biology and tissue develop-
ment associated to cancer and genetic diseases. Hereditary diseases are determined by muta-
tion in Notch-related genes resulting in reduced Notch signaling with consequent altered
development such as Alagille syndrome, spondylocostal dysostosis [4–6] and cerebral autoso-
mal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
[7]. Oppositely, Notch-related cancers are more frequently associated to increased Notch activ-
ity, indicating an oncogenic role of Notch, although a tumor suppressor effect of Notch signal-
ing has also been reported in a minor number of malignancies [2]. Notch signaling gain-of-
function may be acquired by mutations in Notch receptors that, therefore, result constitutively
activated independently from ligand engagement. This is the case of T-cell acute lymphoblastic
leukemia (T-ALL) [8] and other tumors, including breast, ovarian, lung, prostate cancer [2].
On the other side, Notch signaling may be hyperactive although Notch activation still depends
on ligand engagement. This occurs when Notch signaling is dysregulated due to i) increased
copy number or hyperexpression of Notch receptors and ligands [9–12]; ii) altered expression
of regulative elements, such as Skeletrophin that controls Jagged2 activity [13] or Fbw7 that
negatively regulates the stability of ICN [14]; iii) constitutive activation of upstream pathways,
i.e. NF-κB, AKT, Wnt, mTOR, or hypoxic and inflammatory tumor microenvironment, i.e.
IL6, TNFα [15–17]. In all these cases, uncoupling the interaction between Notch and its
ligands is a critical step to hamper Notch aberrant activation.
Current therapeutic approaches of Notch inhibition mainly rely on the use of γ-secretase
inhibitors (GSIs) that indirectly block the activation of all four Notch receptors by inhibiting
the enzymatic activity of the γ-secretase complex [11]. GSIs do not exclusively inhibit Notch
activation, but affect more than 50 further γ-secretase substrates including amyloid precursor
protein, E-cadherin, N-cadherin, LDL receptor-related protein, ErbB-4, etc [18]. Moreover,
GSIs display important side effects on intestinal toxicity due to intestinal goblet cell metaplasia
associated to pan-Notch I inhibition [19]. This prompted the development of novel selective
and direct approaches to inhibit Notch activation. Up to now, the selectivity has been obtained
developing antibody-based drugs directed against Notch receptors (i.e. Notch1, Notch2 and
Notch3), and the Dll4 ligand [11].
This work aims at laying the basis of an unprecedented approach directed to uncouple the
interaction of Notch receptors and ligands by using specific small molecules that offer the
advantages of an oral administration route and no need of nosocomial admission with a conse-
quent better patient’s quality of life and lower social costs. In particular, here we have directed
our first effort to inhibit Notch2 activation trigged by the ligand Jagged2 on the basis of our
interest in multiple myeloma, an hematological malignancy associated to Notch2/Jagged2 dys-
regulation. Multiple myeloma is a deadly disease still incurable in which the high levels of
Notch signalling affects both tumor cell biology and the interactions with the surrounding
microenvironment, inducing a pro-tumorigenic phenotype. We recently showed that Notch2
expression was significantly increased in myeloma patients carrying the high-risk transloca-
tions t(14;16)(q32;q23) and t(14;20)(q32;q11) resulting in Notch signalling activation [17].
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This effect is attributable to Notch2 transactivation triggered by C-MAF and MAFB, the two
transcription factors hyper-expressed by the two transclocations [20]. Notch2 activation may
also be triggered by Dll1 on surrounding stromal cells resulting in the development of bortezo-
mib resistance [21]. On the other side, Notch2 signalling triggered in osteoclast precursors by
myeloma cell-derived Jagged ligands is key in activating tumor-associated osteoclast differenti-
ation and bone destruction [22]. Concerning the Jagged2 ligand, the dysregulation is an early
event occurring in the benign phase of monoclonal gammopathy of uncertain significance as a
consequence of different genetic and epigenetic mechanisms [13,23] and play a key role in
prompting bone marrow stromal cells to support myeloma cell growth by releasing key cyto-
kines including IL-6, IGF-1, VEGF [17,24]. Finally, Jagged2 has been reported as critical for
MM cell self-renewal in vitro and ex vivo [25].
In this study, based on an integrated high-throughput screening (HTS), we combine pro-
tein::protein molecular docking, homology modelling and a virtual screening of a large chemi-
cal library to select in silico a set of small molecules able to disrupt the Notch2::Jagged2
complex. The two top-scoring compounds were validated for their biological activity. This
approach represents a successful strategy to identify small molecules which directly antagonize
Notch signaling activation and display anti-proliferative effect.
Materials and methods
Notch2::Jagged2 molecular modelling
All the computational procedures were carried out using the suite Molecular Operating Envi-
ronment (MOE), 2013.08 (Chemical Computing Group Inc., Montreal, QC, Canada).
In order to obtain a model of the complex between Notch1 and Jagged1, their crystallo-
graphic structures 2VJ3 and 2VJ2 (released on 2008-07-29, [26], respectively, were obtained
from RCSB PDB (http://www.rcsb.org/pdb/home/home.do; 2014, January) and submitted to
an automated procedure for correcting structures and preparing macromolecular data,
through the MOE ‘Protein preparation’ program. The two proteins were docked, using the
ZDOCK Sever version 3.0.2 (http://zdock.umassmed.edu/; 2014, January) [27] and driving the
docking with some of the residues identified as relevant for the interaction between Notch and
Jagged: i.e., Pro199, Arg201; Arg203; Asp205, Pro207 and Ile335 in Jagged with Val453 and
Gly472 in Notch [26]. We analysed the 10 top-scoring complexes according to the ZDOCK score,
and selected the ones recapitulating the experimental interactions. The Notch2::Jagged2 complex
was built by comparative modelling on the Notch1-Jagged1 structures previously computed,
through the MOE ‘Homology Model’ application, using default conditions. Briefly, as a first step,
the primary structures of human Notch2 (Q04721) and Jagged2 (Q9Y219) were obtained from the
UniProt database (http://www.uniprot.org/) and aligned against the sequences of Notch1 (P46531)
and Jagged1 (P78504), respectively, with the MOE ‘Alignment tool’, in order to produce a reference
alignment between the target sequences and the templates for the homology modelling procedure.
Ten independent models of the main chain were built by the Boltzmann-weighted randomized
modelling procedure, and one sidechain model was built for each one of these main chains using
the unary quadratic optimization (UQO) procedure [28]. Each single intermediate model of the
ensemble was submitted to a brief series of highly tethered energy minimizations (EMs), meant
only to relieve steric strain, and scored according to the GB/IV scoring function [29]. On the top
scoring model, the ionization states and proton placement were optimized with the Protonate 3D
application, prior to the final refinement step through EM procedure to a RMS gradient value of
0.5 kcal/mol Å. In all the molecular mechanics procedures (MM), the Amber12:EHT forcefield was
used.
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Notch2::Jagged2 molecular docking
An Asinex database of 438,407 commercial 2D compounds, providing diverse and cost effec-
tive coverage of drug-like chemical space, was selected (www.asinex.com). The majority of the
included compounds have a high degree of drug-likeness, in accordance with Lipinski’s rule of
5. All the entries were in silico pre-processed with the MOE ‘Database Wash’ tool to correct
systematic structure errors and badly-scaled bond lengths, add explicit hydrogen atoms, rebal-
ance protonation states by deprotonating strong acids and/or protonating strong bases,
remove explicit counter-ion and solvent structures, convert them in 3D and energy minimize
their structures through the MOE ‘Database Minimize’ tool with the MMFF94x forcefield. All
the rotatable bonds have been subsequently extensively explored through the MOE ‘Dock’ pro-
cedure as described below.
The dataset was tested via a well-established high throughput screening (HTS) protocol,
performed only on the Notch2 surface, previously identified to interact with Jagged2. In order
to speed-up the HTS procedure, we used a two-step docking protocol, in which each step was
characterized by a different ability to prioritize compounds.
As a first step, the ‘Virtual Screening’ protocol, as implemented in the MOE ‘Dock’ applica-
tion, was applied on the whole dataset of compounds, in which only the top-scoring solutions
for each entry is submitted to the subsequent refinement steps. Briefly, all the rotatable bonds
were explored for each compound, generating 20,000 conformers. The placement methodol-
ogy was set to Triangle matcher, in which poses were generated by superposition of ligand
atom triplets and triplets of receptor site points. The receptor site points were alpha sphere
centers which represent locations of tight packing. At each iteration, a random conformation
was selected. A random triplet of ligand atoms and a random triplet of alpha sphere centers
were used to determine the pose. The maximum number of poses returned by each ligand
placement was set to 1,000. These 1,000 poses were ranked according to the empirical scoring
function London dG [30] and duplicated poses were removed.
In detail, according to the MOE ‘Docking’ documentation, the London dG scoring function
estimates the free energy of binding of the ligand from a given pose. The functional form is a
sum of terms:
DG ¼ cþ Eflex þ
P
h  bondscHBfHB þ
P
m  ligcMfM þ
P
atoms iDDi ð1Þ
where c represents the average gain/loss of rotational and translational entropy; Eflex is the
energy due to the loss of flexibility of the ligand (calculated from ligand topology only); fHB
measures geometric imperfections of hydrogen bonds and takes a value in [0,1]; cHB is the
energy of an ideal hydrogen bond; fM measures geometric imperfections of metal ligations and
takes a value in [0,1]; cM is the energy of an ideal metal ligation; and Di is the desolvation
energy of atom i. The difference in desolvation energies was calculated according to the for-
mula
DDi ¼ ciR
3
i f∭u=2A[Bjuj
  6 du   ∭u=2Bjuj
  6 dug ð2Þ
where A and B are the protein and/or ligand volumes with atom i belonging to volume B; Ri is
the solvation radius of atom i (taken as the OPLS-AA van der Waals sigma parameter plus 0.5
Å); and ci is the desolvation coefficient of atom i. The coefficients {c, cHB, ci} were fitted from
approximately 400 X-ray crystal structures of protein-ligand complexes with available experi-
mental pKi data. Atoms were categorized into about a dozen atom types for the assignment of
the ci coefficients. The triple integrals were approximated using Generalized Born integral
formulas.
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The 25 top-scoring compounds, obtained from the initial ‘Virtual Screening’ protocol, were
resubmitted to a second, more extensive docking procedure, consisting of two docking phases,
placement and refinement. The first step was performed according to the previously described
method, but, instead of keeping only one pose per compound, a higher number (30) of solu-
tions were retained for each protein::ligand complex. Moreover, the 30 the top-scoring com-
plex according to the London dG empirical scoring function were submitted to a further
refinement step based on MM and the resulting complex was rescored according to the GBVI/
WSA ΔG empirical scoring function, in order to obtain an approx. binding free energy value
[30].
In detail, the refinement procedure was carried out considering the receptor as a rigid
structure.
In order to speed up the calculation, residues over a 6 Å cutoff distance away from all the
pre-refined poses were ignored, both during the refinement and in the final energy evaluation.
However, if after the refinement any poses were moved to within 80% of the cutoff distance of
any ignored atoms, the refinement stage was repeated with an increased cutoff distance.
According to the MOE ‘Docking’ documentation [31] the GBVI/WSA ΔG is a forcefield-
based scoring function which estimates the free energy of binding of the ligand from a given
pose. It was trained using the MMFF94x and AMBER99 forcefield on the 99 protein-ligand
complexes of the SIE training set [30]. The functional form is a sum of terms:
DG  cþ a
2
3
ðDECoul þ DEsolÞ þ DEvdW þ bDSAweighted
 
ð3Þ
where:
c represents the average gain/loss of rotational and translational entropy; α, β are constants
which were determined during training (along with c and are forcefield-dependent; ECoul is
the coulombic electrostatic term which is calculated using currently loaded charges, using a
constant dielectric of εi = 1; Esol is the solvation electrostatic term which is calculated using
the GB/VI solvation model. For more information on the GB/VI solvation model, please see
Potential Energy Selection and Configuration; EvdW is the van der Waals contribution to bind-
ing; SAweighted is the surface area, weighted by exposure. This weighting scheme penalizes
exposed surface area.
All the docking procedure were performed with the MOE ‘Dock’ module, and the
Amber12:EHT forcefield.
For the two top-scoring compounds, the final ligand::protein complexes were optimized
and their binding free energy values were computed through a collection of MOE procedures
for interactive ligand modification, geometry optimization and MM-based energy minimiza-
tion in the active site, namely LigX. In detail, during these calculations, the receptor atoms far
from the ligand were held fixed, while receptor atoms in the active site were allowed to move
but subjected to tether restraints to discourage gross movement. The ligand atoms were con-
figured as free to move.
The binding site was automatically identified selecting the interacting residues on the
Notch2::Jagged2 interface through the specific MOE ‘Protein contact’ tool. All the residues
described by Cordle et al [26] and used for the guided Z-Dock procedure were included in this
subset.
For summarizing the interactions between ligands and proteins, a fingerprint scheme was
used, as implemented in the MOE software [32], in which interactions and surface contacts
are classified according to the residue of origin, and built into a fingerprint scheme which is
representative of the database of protein-ligand complexes.
Identification of new small molecules uncoupling the Notch::Jagged interaction
PLOS ONE | https://doi.org/10.1371/journal.pone.0182640 November 3, 2017 5 / 18
A scheme summarizing the in silico HTS pipeline is reported in S1 Fig.
Cell lines and reagents
The human MM cell lines, U266 (ATCC1 TIB-196™) and HEK293 (ATCC1 CRL-1573™)
were purchased from the American Type Culture Collection, KMS12 were purchased from
DSMZ collection of microorganisms and cell cultures. U266 and KMS12 were grown in
RPMI1640 (Lonza, Italy) and HEK293T cell line was grown in DMEM (Lonza, Italy); both
media were supplemented with 10% heat-inactivated FBS (Euroclone, Italy), 2 mM L-Gluta-
mine (Euroclone, Italy), 100 U/ml Penicillin and 100 μg/ml Streptomycin (Sigma-Aldrich,
Germany).
DAPT (GSI-IX, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester)
was purchased from Sigma-Aldrich, reconstituted in DMSO and administered to cells at a
final concentration of 25 μM. Three compounds selected from the docking procedure, namely
BAS 00693376, BAS 00327971 (named from here on as IGOR1 and IGOR2, respectively), and
ASN13406980 (used as negative control), were purchased from Asinex (www.asinex.com) and
reconstituted in DMSO at a concentration of 50 mM.
Notch reporter assay
HEK293T cells were transiently transfected using Turbofect (Fermentas, Italy) with a firefly
luciferase reporter plasmid carrying a multimerized 6xCSL (CBF1-RBP-J) Notch responsive
element [33] and a plasmid carrying the Renilla luciferase under the control of thymidine
kinase promoter (TK-pRL), which provides an internal control for transfection for normaliza-
tion. Immediately after transfection, cells were treated with the selected compounds IGOR1
and IGOR2, DAPT or vehicle (DMSO) at the indicated concentrations. After 48 h of incuba-
tion, luciferase activity was measured in triplicate by Dual-Luciferase Reporter Assay System
(Promega).
Cell growth assay
MM cell lines were seeded in quadruplicate at 50,000 cells/ml in 96-well plate and treated with
different concentrations of the compounds, DAPT or vehicle. DAPT treatment was repeated
every 48 h. After 48 h and 96 h of incubation, cell growth was assessed by the volumetric count
function for alive cells of the BD FACSVerse™ flow cytometer (BD Bioscience, Italy). Assays
were performed in triplicate.
Statistical analysis
Data are presented as mean values ± standard deviation (SD) of at least 3 independent experi-
ments. Statistical analysis was performed by unpaired two-tailed Student’s t-test.
Results and discussion
In silico identification of small molecules disrupting Notch2::Jagged2
interactions
In order to identify novel small molecules able to inhibit the interaction between Notch2 and
Jagged2, we implemented the following strategy: (i) protein::protein docking of crystallo-
graphic structures of Notch1 with Jagged1, guided through the residues known to be located at
the Notch1::Jagged1 interface [26]; (ii) comparative modelling of the complex Notch2::Jag-
ged2, built using the complex from (i); (iii) an in silico HTS directed to Notch2 interaction
Identification of new small molecules uncoupling the Notch::Jagged interaction
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surface of a virtual chemical library containing a large variety of molecules, including very
diverse chemical structures [34].
Molecular modelling of the Notch2::Jagged2 complex. We carried out the protein::pro-
tein docking procedure between Notch1 and Jagged1 by driving it through a set of experimen-
tally identified and highly-conserved residues that have been demonstrated to be involved in
the regulation of the disulphide-rich Delta/Serrate/LAG-2 (DSL) domain: Val453 and Gly472,
for Notch1, and Phe199, Arg201, Arg203, Asp205, Phe207, for Jagged1 (details in Materials
and Methods). The default ZDOCK set-up generates 2,000 solutions, and 1,868 out of these
2,000 were filtered out because of atom clashes.
The ten top-scoring solutions out of the 137 generated ones, according to the ZDOCK
score [35] were carefully analyzed. Only two out of the ten docking solutions satisfied all the
previous residue interactions and were characterized by a low root mean square deviation
value (RMSD, 3.97 Å) after α-carbon superposition, and by the same potential energy value
after minimization. The obtained supramolecular complexes allowed us to exactly identify the
interaction surfaces relevant for the molecular recognition between Notch2 and Jagged2.
Because of the degeneracy of the two selected complexes (potential energy: -3,384 versus
-3,388 kcal/mol), just one of them was selected for further computational analyses.
Notch2::Jagged2 complex was prepared by comparative modelling based on the use of the
previous Notch1::Jagged1 complex as a template. The alignment at the basis of the modelling
procedure was characterized by a very high number of identical residues: 53% Notch1 versus
Notch2, and 51% Jagged1 versus Jagged2. The analysis of the Notch2::Jagged2 interaction sur-
face, carried out with the support of the MOE ‘Protein contact tool, allowed us to retrieve the
conserved residues Ile457, Gly476, for Notch2; Phe210, Arg212, Arg214, Asp216, Phe218 in
Jagged2, corresponding to the same residues in Jagged1, as reported in Fig 1.
The interaction surfaces of Notch2::Jagged2 complex computed as Van der Waals accessible
surface is reported in S2 Fig.
Since our inhibitory strategy was focused on the identification of novel small molecules
able to selectively disrupt Notch::Jagged interaction, in order to avoid unspecific interfering
with the Notch-independent Jagged signaling [36,37], we decided not to use the structure of
the complex, but to carry out the in silico HTS only on the Notch2 interaction surface. In the
first docking step, 435,835 out the original 438,407-compound database were retained. Fig 2A
reports the docking scores (kcal/mol) obtained after the first virtual screening phase for all
435,835 docked compounds, computed through the London dG empirical scoring function. In
this first preliminary screening phase, these values have been used just for relatively ranking
the tested compounds, since they are affected by a significant level of approximation.
The top-scoring 25 molecules define a curve characterized by high first derivative values,
which reduce for subsequent compounds, so a binding free energy cut-off value of -15.75 kcal/
mol was set for compound selection. The compounds with binding free energy above -15.75
(kcal/mol) were instead discarded. The 25 selected molecules were submitted to a more exten-
sive docking procedure, in which the docking score for each protein::ligand complex was com-
puted through the GBVI/WSA dG scoring function. This procedure allows for a more
accurate estimation of the affinity (see Table 1).
Thirty poses for each of the top-scoring 25 compounds were analysed according to the Pro-
tein Ligand Interaction Fingerprint (PLIF) procedure (Fig 2B), and they were demonstrated to
target the Notch2 residues already identified as the key partners in Notch1::Jagged1 interac-
tion, used as a guide during the protein::protein docking procedure, as previously described.
A detailed map of the interaction types engaged by each residue after the accurate docking
phase with the 25 top-scoring compounds are reported in Table 2. For an easier reading, only
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the best score for each ligand is reported. S3 Fig shows their two-dimensional (2D) chemical
structure.
As shown in Fig 2B and in Table 2, all the 25 top-scoring ligands are involved in a diffuse
set of polar and non-polar interactions with the surrounding resides, among which Cys444,
Lys446, Gly447, Ile457, Gly777 seem to be the most relevant ones.
Fig 1. Notch2::Jagged2 complex. (A) Notch2::Jagged2 complex obtained by protein::protein docking followed by homology modelling, shown as whole
representation. Notch2 is shown as purple ribbon; Jagged2 is shown as yellow ribbon. Residues involved in Notch2::Jagged2 contacts are highlighted by
shells rendered according to van deer Waals distance. Conserved residues at the interface of the complex are shown in stick representation. (A’) Notch2::
Jagged2 detailed view.
https://doi.org/10.1371/journal.pone.0182640.g001
Identification of new small molecules uncoupling the Notch::Jagged interaction
PLOS ONE | https://doi.org/10.1371/journal.pone.0182640 November 3, 2017 8 / 18
All the 25 top-scoring poses were carefully analyzed and the 2D ligand interaction plot was
generated and summarized in Table 2.
Two compounds, named IGOR1 and IGOR2, able to specifically target the Notch2 residues
engaged by the Jagged2 interaction, were selected and submitted to a final refinement proce-
dure with LigX, allowing the relaxation of the complex, through a tethered refinement of the
protein binding site and an in situ MM-based ligand optimization. The optimized ligand::pro-
tein complexes obtained for the selected compounds are reported in Fig 3A and 3A’, for
IGOR1, and in Fig 3B and 3B’, respectively. This approach allowed us to compute a more accu-
rate binding free energy and Kd value for the two selected compounds: -4.96 kcal/mol and
223.8 μM for IGOR1, and -5.94 kcal/mol and 42.5 μM for IGOR2, respectively.
The two IGOR compounds were evaluated for their biological efficacy.
Biological effect of selected IGOR compounds
We evaluated the ability of 2 out of 438,407 tested compounds to inhibit Notch activity by
measuring changes in Notch transcriptional activity through a Notch-responsive gene reporter
assay (Fig 4). The Notch-responsive assay allows to measure its transcriptional activity through
ICN-CSL association using a reporter plasmid containing a firefly luciferase gene under the
Fig 2. Virtual high-throughput screening on Notch2 interaction surface. (A) Plot of the docking score
according to the London dG empirical scoring function for the resulting 435,835 compounds after the first
virtual screening docking phase. The Y axis reports the docking score (kcal/mol) of the unique pose obtained
for each tested entry (X axis). These values are sorted according to ascending docking score values along the
Y axis. (B) Protein Ligand Interaction Fingerprint between Notch and the 30 retained docking poses for all the
25 best-scoring compounds tested in the second docking phase. The barcode display represents each
docking pose (row) and protein::ligand fingerprints bit (column) as a matrix, in which a set bit is drawn as a
black rectangle; the X-axis shows the residue that corresponds to each group of fingerprint bits, and is coded
with an arbitrary sequence of colors.
https://doi.org/10.1371/journal.pone.0182640.g002
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control of multimerized (6x) CSL responsive element upstream of a minimal promoter.
HEK293T cells were transfected with the 6xCSL plasmid and pRL-TK (to normalize for the
transfection efficiency) and treated with IGOR1 and IGOR2 for 48 h. The screening concen-
trations were set up starting from the computational dissociation constants (Kd) and within a
concentration range that allowed to maintain the solvent concentration (DMSO) minor than
1%, to avoid any toxic effect. As a positive control of Notch activity inhibition, we used the γ-
Secretase inhibitor, DAPT 25 μM. As a negative control, among the whole database of docked
compounds, we selected a representative compound (ASN13406980, entry number 26 in
Table 1) that, according to our in silico predictions, was assumed not to interfere with Notch2
due to its low affinity. Its binding free energy value was indeed significantly lower than that
computed for IGOR1 and IGOR2 (in Table 1, entry number 8 and 1, respectively).
IGOR1 and 2 significantly reduced Notch transcriptional activity in a dose-dependent man-
ner (Fig 4). IGOR1 exerted an inhibitory effect with an IC50 (33.75 ± 0.28 μM) lower than
IGOR2 (IC50 283.00 ± 29.52 μM). In particular, the effect of 30 μM IGOR1 displayed an effi-
cacy similar to 25 μM DAPT.
Computational (affinity for Notch2) and experimental results (ability to uncouple Notch2::
Jagged2 interaction) cannot be compared, since the ability of uncoupling Notch2::Jagged2
interaction is not only and directly connected to the affinity of these Notch2 ligands, but also
Table 1. Binding free energy of the 25-top scoring compounds after HTS.
Virtual Screening Accurate docking
Compound Binding free energy (kcal/mol) Binding free energy (kcal/mol)
1 -15.95 -8.19
2 -15.85 -7.30
3 -15.77 -6.96
4 -16.03 -6.88
5 -16.66 -6.72
6 -15.74 -6.59
7 -17.10 -6.49
8 -18.04 -6.48
9 -16.08 -6.46
10 -15.97 -6.39
11 -17.11 -6.29
12 -16.18 -6.26
13 -15.83 -5.99
14 -16.77 -5.77
15 -16.37 -5.77
16 -16.03 -5.74
17 -16.42 -5.72
18 -16.44 -5.67
19 -15.78 -5.61
20 -15.91 -5.49
21 -16.12 -5.35
22 -15.77 -5.28
23 -15.86 -5.27
24 -15.77 -4.70
25 -17.36 -4.12
26 -8.04 -
https://doi.org/10.1371/journal.pone.0182640.t001
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depends on other structural and physico-chemical properties that influence their ability to
unfavour the Notch2::Jagged2 molecular recognition.
On the other side, we believe that further steps of chemical refinement could be useful to
increase the potency of IGOR2, whose IC50 is currently too high to exclude the presence of a
toxic non-specific effect.
The effect of the selected compounds on cell viability was assessed. Cell growth assay was
performed on two multiple myeloma cell lines, U266 and KMS12. These cells carry the dysre-
gulated Notch pathway mainly due to a high expression of Notch2 receptors, and Jagged
ligands; specifically, U266 cells exclusively express Notch2 and KMS12 cells express both
Notch 1 and Notch2, with a prevalence of the second [24,25,38,39]. Therefore, these cells rep-
resent a suitable model to evaluate the biological outcome of Notch2 activation blockade
induced by our compounds. Cell viability was evaluated, through flow cytometry, after 48h
Fig 3. In silico complexes between Notch2 and the IGOR compounds. (A, B) Best docking poses of the IGOR compounds, selected through
virtual HTS on Notch2 homology model. Notch2 is shown as ribbon; residues in the active site are shown in stick representation; IGOR1 and IGOR2
are shown in stick representation in A and B, respectively. (A’, B’) Two-dimensional ligand interaction scheme of IGOR compounds. Polar and greasy
residues are shown in lilac and lime respectively; acidic and basic residues are highlighted by red and blue contours, respectively. Residues involved in
protein::ligand interactions are highlighted by green arrows; proximity contour by dotted lines.
https://doi.org/10.1371/journal.pone.0182640.g003
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and 96h of incubation with different concentrations of IGOR1 and IGOR2 (Fig 5). We
observed that the treatment with 30 μM and 40 μM IGOR1 for 48 h and 96 h induced a dose-
dependent inhibition of cancer cell growth, respectively 45.8% and 62.6%, for U266 cells and
46.0% and 57.6%, for KMS12 cells at 96 h. This effect was comparable to that of DAPT (respec-
tively 46.4% and 33.1% cell growth for U266 and KMS12 cells at 96 h). IGOR2 was less effec-
tive and showed an inhibitory effect at higher concentrations: 300 μM IGOR2 induced a cell
growth inhibition of 39.7% in U266 cell line and 39.1% in KMS12 cells.
On the whole, the inhibitory effect on cancer cell viability of the two compounds directed
specifically to inhibit the activation of Notch receptors triggered by Jagged ligands was compa-
rable to that of GSI. This is in accordance with our previous results indicating that Notch sig-
naling inhibition obtained by silencing Jagged1 and 2 results in decreased U266 cell growth
[17] and osteoclastogenic potential [22].
Fig 4. Inhibitory effect of the IGOR compounds on Notch transcriptional activity. A Notch-
responsive luciferase assay was carried out on HEK293T cells treated with different concentrations of
IGOR1 and IGOR2, the positive and negative controls DAPT and ASN13406980, respectively. After 48 h
of incubation luciferase activity was measured by dual luciferase reporter assay. Data are expressed as
mean value ± SD of three experiments. Statistical analysis was performed by unpaired two-tailed Student’s
t-test. *** = p < 0.001; ** = p < 0.01; * = p < 0.05.
https://doi.org/10.1371/journal.pone.0182640.g004
Fig 5. Effect of the IGOR compounds on MM cell viability. (A, B) Cell growth assay of U266 and KMS12
cells upon treatment with IGOR1 and IGOR2. Viability of MM cells was assessed by the volumetric count
function of the FACS Verse BD flow cytometer. The values are mean ± SD. Statistical analysis was performed
by unpaired two-tailed Student’s t-test. *** = p < 0.001; ** = p < 0.01; * = p < 0.05.
https://doi.org/10.1371/journal.pone.0182640.g005
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Conclusions
This work represents an efficient and integrated strategy spanning in silico and in vitro
approaches useful to identify, test and validate novel compounds able to disrupt the Notch::
Jagged interaction, switching off the subsequent signalling pathway.
The use of molecular modelling tools allowed us to specifically target, at an atomistic level,
the Notch residues involved in the Notch::Jagged molecular recognition mechanism, without
perturbing the activation of Notch pathways not mediated by Jagged, and without altering the
other Jagged functions [36,37].
Comparative modelling procedures applied to the structural study of Notch has been vali-
dated in vitro by the identification of active IGOR compounds able to inhibit the Notch signal-
ling pathway. In this paper, we mainly focused our attention on Notch2, which plays a key role
in multiple myeloma [17,21,22] and other hematological malignancies, including splenic mar-
ginal zone lymphoma [40], B-cell chronic lymphocytic leukemia [41] and diffuse large B-cell
lymphomas [42] as well as in other solid cancers including glioma [43], lung adenocarcinoma
[44], oesophageal squamous cell carcinoma [45], cervical cancer [46], hepatocellular carci-
noma [47], gastric cancer [48] and pancreatic carcinoma [49]. Even if, at the moment, no
molecular data about the selectivity of IGOR compounds with respect to the different Notch
isoforms are available, the growth inhibition of U266 cells, which carry exclusively Notch2,
suggested the IGORs ability to target this isoform.
These results lay the foundations for the development of an integrated pipeline to further
identify selective Notch inhibitors through a differential comparative modelling of all the
Notch isoforms suitable for improving the proposed pipeline. If selective compounds will be
identified, this approach promises to overcome gut toxicity induced by common pan-Notch
inhibitory drugs, i.e. GSIs. Indeed, a recent report indicates that intestinal toxicity can be
avoided through the selective inhibition of Notch activation mediated only by Jagged ligands
or alternatively by Dll ligands [19].
The present approach provides the proof of concept that it is possible to target Notch::
Jagged interaction via small molecules, and poses the bases for future pharmacological strat-
egies aimed at operating on this signaling pathway by an unprecedented strategy. Indeed,
small molecules have several advantages with respect to biotechnological drugs, since they
can be easily delivered, are metabolically stable and orally active. Additionally, their admin-
istration does not need inpatient treatment thereby improving patients’ quality of life and
reducing social costs.
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